Absorption Systems (Exton, Pennsylvania) reported the results of a study demonstrating the power of its CellPort Technologies to predict the potential for pharmacokinetic drug-drug interactions. The study, published online in Drug Metabolism and Disposition examined AstraZeneca's (London) ximelagatran and its active metabolite, melagatran, both of which are actively secreted into bile. (Medical Device Daily) Read More
